ANRIL has been found to be up-regulated in leukemia, prostate cancer, basal cell carcinoma and glioma, whereas depletion of ANRIL has been implicated in reduced proliferation, indicating its role in cancerogenesis [51-53]. Here, CDKN2B-AS1 is linked to leukemia.